![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Stachanow, Viktoria; Neumann, Uta; Blankenstein, Oliver; Fuhr, Uwe; Huisinga, Wilhelm; Michelet, Robin; Reisch, Nicole und Kloft, Charlotte
(2021):
Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling.
In: European Journal of Endocrinology, Bd. 185, Nr. 3: S. 365-374
Ullah, Sami; Zoller, Michael; Jaehde, Ulrich; Huseyn-Zada, Mikayil; Weig, Thomas; Fuhr, Uwe; Arshad, Usman; Zander, Johannes und Taubert, Max
(2021):
A Model-Based Approach to Assess Unstable Creatinine Clearance in Critically Ill Patients.
In: Clinical Pharmacology & Therapeutics, Bd. 110, Nr. 5: S. 1240-1249
Li, Xia; Zoller, Michael; Fuhr, Uwe; Huseyn-Zada, Mikayil; Maier, Barbara; Vogeser, Michael; Zander, Johannes und Taubert, Max
(2019):
Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose.
In: Journal of Antimicrobial Chemotherapy, Bd. 74, Nr. 3: S. 682-690
Taubert, Max; Zander, Johannes; Frechen, Sebastian; Scharf, Christina; Frey, Lorenz; Vogeser, Michael; Fuhr, Uwe und Zoller, Michael
(2017):
Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens.
In: Journal of Antimicrobial Chemotherapy, Bd. 72, Nr. 8: S. 2304-2310
Taubert, Max; Zoller, Michael; Maier, Barbara; Frechen, Sebastian; Scharf, Christina; Holdt, Lesca-Miriam; Frey, Lorenz; Vogeser, Michael; Fuhr, Uwe und Zander, Johannes
(2016):
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.
In: Antimicrobial Agents and Chemotherapy, Bd. 60, Nr. 9: S. 5254-5261
Loibl, Sibylle; Rokitta, Dennis; Conrad, Bettina; Harbeck, Nadia; Wüllner, Michaela; Warm, Mathias; Schwedler, Kathrin; Gerber, Bernd; Schrader, Iris; Eidtmann, Holger; Mehta, Keyur; Fuhr, Uwe und Minckwitz, Gunter von
(2014):
Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.
In: Breast Care, Bd. 9, Nr. 3: S. 169-174
[PDF, 187kB]